The pharmaceutical industry held a business analysis meeting in the first half of the year.
Release time:
2020-08-14
Pharmaceutical held a first-half business analysis meeting
called for invigorating spirit, pioneering and innovating, and striving to complete the annual target task
News from our newspaper 7# October 10 , Pharmaceutical Company held a first-half business analysis meeting in Jinxi Pharmaceutical Factory to summarize the work in the first half and arrange the work plan for the second half.
Various departments and subordinate enterprises of Pharmaceutical Company reported their work in the first half of the year and put forward their work plans and objectives for the second half of the year. Chief Financial Officer Gong Xiliang analyzed the operation of Pharmaceutical Company in the first half of the year. General Manager Huang Jinlong summarized the work of the pharmaceutical company in the first half of the year, analyzed the existing problems and difficulties, and made arrangements for the work in the second half of the year.
In the first half of this year, the new medical reform and industry supervision have been strengthened day by day. All employees of the pharmaceutical company have worked hard and achieved a series of new results: the national first-class anti-tumor drug deoxypodophyllotoxin for injection has obtained clinical approval and is expected to be included in the national "13th Five-Year Plan" major new drug creation science and technology major project; Desvenlafaxine Succinate Sustained Release Tablets were included in Jinhua Key Science and Technology Innovation Project; jianfeng Pharmaceutical was named 2016 National Intellectual Property Advantage Enterprise by the State Intellectual Property Office. Signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and completed the first phase of investment. Bidding and negotiation have achieved phased results. Peak natural products continue to maintain a good momentum of development; Major pharmacies have strengthened in-depth cooperation with hospitals and achieved results; the "three downsides and three improvements" have continued to play an important role in tapping internal potential.
Facing the severe external environment and internal operating pressure, the pharmaceutical company will mainly do the following work in the second half of the year: strengthen marketing management and broaden new space for marketing work; Speed up the pace of new drug development, improve efficiency, and improve quality; Standardize management and improve the level of operation and management, from quality management, internal control management, receivables and inventory management, human resource management, three reductions and three improvements, etc, systematically improve the level of internal management; speed up the pace of information construction, promote the process of internationalization, pay close attention to technological transformation projects, and enhance the stamina of enterprise development. At the
meeting, Huang Jinlong asked all employees to cheer up, change pressure into motivation, find ways to promote all kinds of work in a planned, targeted, measured and responsible way, and work hard to achieve the annual goal of the pharmaceutical company. (This correspondent)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page